Momenta is partnered with Sandoz, the generic unit of Novartis AG, based in Basel, Switzerland, for the development of M-Enoxaparin, its generic version of Sanofi-Aventis SA's blood thinner Lovenox...sales in 2009 for its manufacturer, Sanofi-Aventis

Oxford BioTherapeutics Ltd., of Oxford, UK, said Sanofi-Aventis SA, part of Sanofi-Aventis Group, of Paris, acquired an exclusive worldwide license to one of its preclinical antibody programs...Sanofi-Aventis will use the antibody, which is directed against a proprietary target identified by Oxford, to develop antibody drug conjugate products

In June 2010, Sanofi-Aventis SA, of Paris, licensed Pancreate from CureCM LLC, of Wilmington, Del., for up-front and milestone payments totaling as much as $335 million

Most have learned in the past decade that simply sinking more money into internal drug programs doesn't correlate into beefier pipelines, and the new generation of big pharma CEOs – Andrew Witty at GlaxoSmithKline plc, Chris Viehbacher at Sanofi-Aventis SA and Severin Schwan at Roche AG – continue looking more and more toward biotech to fill dwindling portfolios...Of course, his retirement could come sooner, if prospective acquirer Sanofi-Aventis succeeds in nailing down a deal

The next frontier is collaborating with Chinese companies to bring about innovation," Arjun Oberoi, vice president of business development and strategy for the Asia Pacific region at Sanofi-Aventis SA, told attendees during a lunchtime panel

Rumors have abounded on Genzyme, which is the target of an $18.5 billion hostile bid from Sanofi-Aventis SA, but the biotech's leader wouldn't say anything about ongoing discussions or terms of a negotiated transaction with Sanofi-Aventis

Rumors have abounded on Genzyme, which is the target of an $18.5 billion hostile bid from Sanofi-Aventis SA, but the biotech's leader wouldn't say anything about ongoing discussions or terms of a negotiated transaction with Sanofi-Aventis

Negotiations between Genzyme Corp., of Cambridge, Mass., and Sanofi-Aventis SA, of Paris, have expanded to include representatives from both companies, in addition to financial advisers from both companies

Pomerantz Haudek Grossman & Gross LLP on behalf of Genzyme shareholders The law firm filed a class action lawsuit against the company, certain of its top officials and members of the board, claiming a breach of fiduciary duties in connection with a tender offer by Sanofi-Aventis to buy the company for $18.5B

Sanofi-Aventis SA

We are still searching for the ideal model." – Sridaran Natesan, scientific site head for research and development at Sanofi-Aventis SA's Cambridge, Mass

Paris-based Sanofi-Aventis Group and its wholly owned subsidiary, BiPar Sciences, of South San Francisco, announced that The New England Journal of Medicine published the final Phase II data for iniparib (BSI-201) demonstrating significant clinical benefit in women with metastatic triple negative breast cancer (mTNBC) when iniparib was administered in combination with chemotherapy agents gemcitabine/carboplatin

12/30/11 12/30/11 ND Cornerstone acquired Cardiokine for an undisclosed amount Dermik (dermatology unit of Sanofi-Aventis; Paris) Valeant Pharmaceuticals International Inc

January | February | March | April | May | June | July | August | September | October | November | December | December - 2011 Biotech Company Pharma Company Type/Product Area Terms/Details Akorn Inc. H. Lundbeck A/S Akorn's subsidiary, Oak Pharmaceuticals, acquired three off-patent, branded, hospital-based injectables Akorn will make an up-front payment of $45M and a subsequent milestone payment of $15M in cash after three years Amgen Inc. Watson Pharmaceuticals Inc. Deal to develop

for sexually transmitted diseases (12/21) Theratechnologies Inc. (Canada; TSX:TH) Sanofi-Aventis Group SA (France) Commercialization deal for Egrifta in Latin America, Africa and the Middle East Theratechnologies will receive a significant percentage of the drug's selling price in those regions, while Sanofi will be responsible for all regulatory and commercial activities for Egrifta for HIV-associated lipodystrophy

Ltd. (China) Collaboration to develop cancer candidates AT-101 and AT-406 from Ascenta's pipeline AT-101 and AT-406 trigger apoptosis through pan-Bcl-2 inhibition and multi-IAP inhibition, respectively (12/2) Asupex Pharmaceuticals Inc.* Teva Pharmaceutical Industries Ltd. (Israel) Deal involving a deuterium-containing drug Financial terms were not disclosed (12/21) Avila Therapeutics Inc.* Sanofi-Aventis SA (France) Collaboration to design targeted covalent drugs against six

had done 51 deals, just ahead of Sanofi-Aventis SA and Novartis AG with 50 and 49 deals, respectively...Sanofi-Aventis' ranking is a little more impressive, having risen up from 14th place last year

GenVec Inc., of Gaithersburg, Md., signed a deal with Sanofi-Aventis Group SA's Merial animal health division, under which the latter will use the former's adenovector technology to develop and sell a vaccine for foot-and-mouth disease

New Business Models Sridaran Natesan, scientific site head for research and development at Sanofi-Aventis SA's Cambridge, Mass